The Best Way to Further Secure the Pharmaceutical Supply Chain

NCPA

Any reports about contaminated, diverted or fake prescription drugs being taken by unsuspecting patients is a cause for concern. According to the latest figures from the National Community Pharmacists Association (NCPA), America’s independent community pharmacies dispense 1.5 billion prescriptions annually, and those sales represent over 92% of their business. These small business health care providers are committed to ensuring the pharmaceutical supply chain is safe and secure, which occasionally entails offering system-strengthening recommendations.
[Read more...]

Rising to the Challenge: Building Elite Anti-Corruption Compliance Programs

Miller Chevalier

The Anti-Corruption Compliance Challenge for Healthcare.  The healthcare industry has been in the anti-corruption spotlight for a full decade.   Since 2002, at least 37 companies in the healthcare industry have announced investigations, voluntary or otherwise, of potential corrupt payments outside the United States.  In that time, 14 healthcare-related companies have settled enforcement actions relating to payments in roughly 20 countries across all of the major continents, with additional countries represented in ongoing investigations.  Pursuant to the settlements, 8 companies have been required to retain independent monitors to evaluate the companies’ compliance programs and report periodically to the DOJ and the SEC.  In the meantime, the Dodd-Frank whistleblower provisions entered into force, increasing the likelihood that companies will find themselves answering questions from the enforcement agencies about their program.
[Read more...]

Medical Governance and Why it is a Critical Part of a Global Pharmaceutical and Compliance Program

North Highland

Should medical governance be separate from a global compliance program? Some might believe that to be the case, but in my 20 plus years of consulting, I have found medical governance is a critical part of any global compliance program, because it supports innovation, integrity and provides uniformed guidance.  Our industry is challenged with containing healthcare cost and price inequalities, and productivity is at risk in lieu of rising R&D costs, the increasing size of clinical trials, regulatory demands and inadequate R&D strategies. One way to resolve this is to simply align medical governance with a compliance program.
[Read more...]